Clinical trial · no report yet · Phase 3
EVOKE-01
Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- NCT05089734 ↗
- Active not recruiting
- Gilead Sciences
- 102 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 64 | |
| YouTube | 20 | |
| Podcasts | 18 |
The trial
ClinicalTrials.gov- Official title
- Open-Label, Global, Multicenter, Randomized, Phase 3 Study of Sacituzumab Govitecan Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Sacituzumab Govitecan-hziy (SG); Docetaxel
- Arms
- Sacituzumab Govitecan-hziy (SG) · Experimental
- Docetaxel · Active comparator
- Enrollment
- 603
- Primary outcomes
- Overall Survival (OS)
- Sponsor
- Gilead Sciences
- Start
- Nov 17, 2021
- Primary completion
- Nov 29, 2023
- Results posted
- Yes
- Registry record
- NCT05089734 · updated May 7, 2026
Publications
linked from the registry- Paz-Ares LG, Juan-Vidal O, Mountzios GS, Felip E, Reinmuth N, de Marinis F, Girard N, Patel VM, Takahama T, Owen SP, Reznick DM, Badin FB, Cicin I, Mekan S, Patel R, Zhang E, Karumanchi D, Garassino MC. Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study. J Clin Oncol. 2024 Aug 20;42(24):2860-2872. doi: 10.1200/JCO.24.00733. Epub 2024 May 31. PubMed 38843511